碳酸酐酶抑制剂治疗黄斑水肿的机制与进展  

Progress and mechanism of carbonic anhydrase inhibitors for macular edema

作　　者：闵靖宇 宫媛媛[1] 

机构地区：[1]上海交通大学附属第一人民医院眼科,上海市200080

出　　处：《眼科新进展》2016年第7期684-687,共4页Recent Advances in Ophthalmology

基　　金：国家自然科学基金项目(编号:81300774);上海市自然科学基金项目(编号:12ZR1424500);上海市眼底病重点实验室开放课题基金项目(编号:07Z22911)~~

摘　　要：黄斑水肿是一种可继发于多种眼部疾病的病理改变,会导致严重视功能障碍,且治疗方法多样。碳酸酐酶抑制剂作为黄斑水肿的辅助治疗药物,可通过抑制机体碳酸酐酶来调节视网膜色素上皮细胞的泵作用,或直接影响视网膜血管系统,来减轻水肿的症状。目前,常用的碳酸酐酶抑制剂为磺胺类,且针对一些继发于不同病因的黄斑水肿可有不同程度的临床疗效。本文主要对碳酸酐酶抑制剂治疗黄斑水肿的机制与进展作一综述。Macular edema is a pathologic condition secondary to a variety of eye diseases,which may lead to severe vision dysfunction. As an optional auxiliary method in the treatment of macular edema,carbonic anhydrase inhibitor drugs can inhibit the carbonic anhydrase to adjust the pumping action of the retinal pigment epithelium cells,or directly affect retinal vascular system and then reduce symptoms of edema. At present,sulfonamides are the most widely used carbonic anhydrase inhibitor,and it can have different degrees of clinical curative effect due to different causes of macular edema. The mechanism of carbonic anhydrase inhibitor for macular edema and progress are review ed in this article.

关 键 词：黄斑水肿 碳酸酐酶抑制剂 视网膜色素上皮 

分 类 号：R774.5[医药卫生—眼科]